We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Cytokine Signatures of Tertian Malaria Infection Profiled During Pregnancy

By LabMedica International staff writers
Posted on 27 May 2020
Print article
Image: The Cytokine Magnetic 30-Plex Panel is specifically designed for quantifying human cytokines, chemokines and growth factors in serum, plasma, and tissue culture supernatant (Photo courtesy of Invitrogen).
Image: The Cytokine Magnetic 30-Plex Panel is specifically designed for quantifying human cytokines, chemokines and growth factors in serum, plasma, and tissue culture supernatant (Photo courtesy of Invitrogen).
Malaria caused by Plasmodium vivax is a neglected tropical disease, especially during pregnancy, of worldwide distribution. P. vivax is a protozoal parasite and a human pathogen. This parasite is the most frequent and widely distributed cause of recurring malaria.

Severe vivax malaria or tertian malaria is associated with inflammatory responses but in pregnancy immune alterations make it uncertain as to what cytokine signatures predominate, and how the type and quantity of blood immune mediators influence delivery outcomes.

Medical scientists at the Hospital Clínic de Barcelona (Barcelona, Spain) and their international colleagues measured the plasma concentrations of a set of thirty-one biomarkers, comprising cytokines, chemokines and growth factors, in 987 plasma samples from a cohort of 572 pregnant women from five malaria-endemic tropical countries and related these concentrations to delivery outcomes (birth weight and hemoglobin levels) and malaria infection.

The biomarkers were analyzed in thawed plasmas with a multiplex suspension detection system Cytokine Magnetic 30-Plex Panel (Invitrogen, Madrid, Spain) which allows the detection of different biomarker. In addition, the cytokine TGF-β1 was analyzed in all plasmas except those from India, with a DuoSet ELISA kit (R&D Systems, Minneapolis, MN, USA). P. vivax and P. falciparum (studied as a possible confounder in co-infected women) parasitaemia were assessed at every visit in Giemsa-stained blood slides that were read onsite. Submicroscopic malaria infections were also determined at enrolment and delivery by real time-PCR in a group of participants, which included the immunological subcohort. Malaria symptoms and hemoglobin (Hb, g/dL) levels were also recorded at enrolment and delivery, as well as neonatal birth weight (g).

The team reported that at recruitment, they found that P. vivax–infected pregnant women had higher plasma concentrations of proinflammatory (IL-6, IL-1β, CCL4, CCL2, CXCL10) and TH1-related cytokines (mainly IL-12) than uninfected women. This biomarker signature was essentially lost at delivery and was not associated with birth weight or hemoglobin levels. Anti-inflammatory cytokines (IL-10) were positively associated with infection and poor delivery outcomes. CCL11 was the only biomarker to show a negative association with P. vivax infection and its concentration at recruitment was positively associated with hemoglobin levels at delivery. Birth weight was negatively associated with peripheral IL-4 levels at delivery.

The authors concluded that their data showed that while TH1 and pro-inflammatory responses are dominant during P. vivax infection in pregnancy, anti-inflammatory cytokines may compensate excessive inflammation avoiding poor delivery outcomes, and skewness toward a TH2 response that may trigger worse delivery outcomes. CCL11, a chemokine largely neglected in the field of malaria, emerges as an important marker of exposure or mediator in this condition. The study was published on May 4, 2020 in the journal PLOS Neglected Tropical Diseases.

Related Links:
Hospital Clínic de Barcelona
Invitrogen
R&D Systems



Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
FOB+Transferrin+Calprotectin+Lactoferrin Test
CerTest FOB+Transferrin+Calprotectin+Lactoferrin Combo Test
New
Ultrasonic Cleaner
UC 300 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.